Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai Inc and Merck Sharp & Dohme Corp.

Key Highlights From the 2019 European Oncology Meeting: Focus on Emerging Strategies for Solid Tumors

Release Date: October 31, 2019
Expiration Date: October 31, 2020
Media: Internet - based

Activity Overview

Key Highlights From the 2019 European Oncology Meeting: Focus on Emerging Strategies for Solid Tumors provides physicians with updates in solid tumors from the medical oncology meeting held in Barcelona. This activity focuses on endometrial, thyroid, kidney, and liver cancers. Brief summaries of key abstracts are provided, along with expert commentary to provide a critical assessment of the data, as well as with integration into practice, where appropriate.

Benefits of Participating

  • Incorporate practice-changing data in your clinic
  • Learn about emerging therapeutic approaches in solid tumors
  • Gain an understanding of the increasing importance of molecular testing in solid tumors
  • Hear experts discuss management of adverse events with new therapeutic regimens

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc and Merck Sharp & Dohme Corp.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists involved in the treatment and management of patients with cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals (HCPs) interested in the treatment of cancer may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review how tumor-testing strategies have been integrated into the study designs of recently reported clinical trials
  • Recognize practice-changing results to inform improved diagnosis, treatment, and adverse event management for solid tumors
  • Place recent trial evidence into the context of evolving treatment paradigms for cancer management
  • Learn strategies for promoting multidisciplinary best practices in the proactive management of treatment-related toxicities

Faculty, Staff, and Planners’ Disclosures


Jordi Bruix
Jordi Bruix, MD, PhD
Professor of Medicine
University of Barcelona
Director of the BCLC Group (Barcelona Clinic Liver Cancer)
Liver Unit - Hospital Clinic
Barcelona, Spain

Disclosures: Grant Research Support: Bayer, BTG; Consultant: ArQule, Bayer, BMS, BTG, Eisai, Kowa, Terumo, Gilead, Bio Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Meddimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano, Sanofi; Speaker’s Bureau: Bayer, BTG, Ipsen, Eisai, Terumo, Sirtex.

Enrique Grande
Enrique Grande, MD, PhD
Head, Medical Oncology Service
MD Anderson Cancer Center Madrid
Madrid, Spain

Disclosures: Honoraria for ad boards and/or lectures: Pfizer, BMS, Ipsen, Roche, Eisai, EUSA Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, Celgene, Astellas, Janssen, Bayer; Research Grants: Pfizer, AstraZeneca, MTEM/Threshold, Roche, Ipsen, Lexicon, Molecular Templates Inc; Leadership roles in medical societies: ENETS, GETNE, and GETHI.

Bradley J. Monk
Bradley J. Monk, MD, FACS, FACOG
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director
US Oncology Research Network - Gynecologic Program
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Agenus, Amgen, Aravive, AstraZeneca, Asymmetric Therapeutics, Boston Biomedical, ChemoCare, ChemoID, Circulogene, Clovis, Conjupro, Eisai, Geistlich, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Laekna Health Care, Mateon (formerly Oxigene), Merck, Mersana, Myriad, NuCana, OncoMed, OncoQuest, OncoSec, Perthera, Pfizer, Precision Oncology, Puma, Regeneron, Roche/Genentech, Samumed, Takeda, TESARO/GSK, VBL, Vigeo; Speaker: AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, TESARO/GSK.

Thomas Powles
Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Lead for Solid Tumour Research
Barts Cancer Centre
Queen Mary University of London
Director of Barts Cancer Centre
St. Bartholomew’s Hospital
London, England

Disclosures: Grant/Research Support: AstraZeneca, Roche; Consultant: AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By